Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
Status:
Terminated
Trial end date:
2011-07-19
Target enrollment:
Participant gender:
Summary
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult
subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and
200 mg once daily with a control arm of open-label etravirine (ETV) 200 mg twice daily. The
background ART for all three arms will be darunavir/ritonavir (DRV/r) 600 mg/100 mg twice
daily plus raltegravir (RAL) 400 mg twice daily. Antiviral activity, safety, PK, and
development of viral resistance will be evaluated.